Precision BioSciences, Inc. Form 8-K Filing

Precision BioSciences, Inc. announced a Key Opinion Leader (KOL) event on March 17, 2026, to discuss Duchenne muscular dystrophy (DMD). The event featured experts who provided an overview of the PBGENE-DMD program and the FUNCTION-DMD Phase 1/2 clinical trial, focusing on the unmet needs and current treatment landscape for DMD. The company highlighted its ARCUS gene editing platform and its potential in treating various diseases, including DMD. The presentation detailed the PBGENE-DMD therapy, designed to excise a specific region of the dystrophin gene to restore muscle function. Preclinical data showed promising results in terms of dystrophin protein expression, muscle integrity, and functional improvements in DMD mouse models. The FUNCTION-DMD trial is designed for safety and speed, with initial data expected by year-end 2026. The company also provided an update on its PBGENE-HBV program for chronic Hepatitis B.